Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Intellia Therapeutics ( (NTLA) ) has provided an update.
On June 11, 2025, Intellia Therapeutics held its annual stockholders’ meeting, where several key decisions were made. The stockholders approved the 2025 Equity Incentive Plan, elected three directors for a three-year term, ratified Deloitte & Touche LLP as the independent auditor for 2025, and decided on an annual frequency for advisory votes on executive compensation. These decisions are expected to impact the company’s governance and operational strategies.
The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Intellia Therapeutics’ overall stock score is influenced by its robust clinical progress and positive corporate updates, which are offset by financial and valuation challenges common in the biotech industry. The company’s strong R&D pipeline and strategic milestones provide a positive long-term outlook despite near-term financial hurdles.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of gene-editing therapies. The company’s primary products and services include innovative treatments aimed at addressing genetic diseases, with a market focus on advancing CRISPR/Cas9 technology for therapeutic use.
Average Trading Volume: 4,186,939
Technical Sentiment Signal: Sell
Current Market Cap: $877.4M
See more data about NTLA stock on TipRanks’ Stock Analysis page.